Paradigm Capital Management Inc. NY Purchases New Shares in Enovis Corporation $ENOV

Key Points

• Paradigm Capital Management acquired 1.38 million Enovis shares worth approximately $28.5 million in the second quarter, representing about 2.39% of the company. Institutional investors collectively own 98.45% of Enovis.
• Enovis beat quarterly expectations, reporting adjusted earnings of $0.90 per share versus the $0.85 consensus estimate and revenue of $582.78 million. Revenue increased 3.2% year over year, while fiscal 2026 EPS guidance is $3.52–$3.73.
• Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $41.29 compared with the stock’s recent price of $25.15. Recent targets range from $32 to $45, and insiders purchased 4,200 shares during the last quarter.

Paradigm Capital Management Inc. NY acquired a new stake in Enovis Corporation (NYSE:ENOV - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,378,398 shares of the company's stock, valued at approximately $28,533,000. Enovis comprises approximately 0.8% of Paradigm Capital Management Inc. NY's investment portfolio, making the stock its 27th biggest holding. Paradigm Capital Management Inc. NY owned approximately 2.39% of Enovis as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ENOV. First National Bank of Omaha bought a new stake in Enovis during the 2nd quarter worth about $1,250,000. Bernzott Capital Advisors raised its stake in shares of Enovis by 47.4% in the first quarter. Bernzott Capital Advisors now owns 294,125 shares of the company's stock worth $6,691,000 after acquiring an additional 94,529 shares during the last quarter. Front Street Capital Management Inc. lifted its position in shares of Enovis by 106.1% during the first quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company's stock worth $16,973,000 after purchasing an additional 384,124 shares in the last quarter. Invenomic Capital Management LP lifted its position in shares of Enovis by 6.2% during the fourth quarter. Invenomic Capital Management LP now owns 756,717 shares of the company's stock worth $20,159,000 after purchasing an additional 44,048 shares in the last quarter. Finally, Fifth Third Bancorp lifted its position in shares of Enovis by 50,442.8% during the first quarter. Fifth Third Bancorp now owns 83,901 shares of the company's stock worth $1,909,000 after purchasing an additional 83,735 shares in the last quarter. Institutional investors own 98.45% of the company's stock.

Enovis Price Performance

ENOV opened at $25.15 on Tuesday. The stock has a market cap of $1.45 billion, a P/E ratio of -1.31 and a beta of 1.34. Enovis Corporation has a 12 month low of $19.14 and a 12 month high of $34.28. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The company has a fifty day simple moving average of $25.31 and a 200 day simple moving average of $24.19.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same period in the previous year, the company posted $0.79 earnings per share. The company's revenue for the quarter was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts expect that Enovis Corporation will post 3.15 EPS for the current year.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert acquired 1,200 shares of the business's stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider directly owned 51,840 shares of the company's stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders bought 4,200 shares of company stock worth $92,084. Insiders own 2.90% of the company's stock.

Analysts Set New Price Targets

Several research firms recently weighed in on ENOV. Zacks Research upgraded shares of Enovis from a "strong sell" rating to a "hold" rating in a research report on Wednesday, July 29th. Evercore set a $32.00 price objective on Enovis in a research report on Monday, July 6th. Canaccord Genuity Group lowered their target price on Enovis from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Monday, August 17th. Wells Fargo & Company dropped their target price on Enovis from $40.00 to $39.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. Finally, BTIG Research upped their price target on Enovis from $39.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Enovis currently has an average rating of "Moderate Buy" and an average target price of $41.29.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.